Liver Damage and Cardiometabolic Disorders in NAFLD
Recruiting
Observational Study
NAFLD
Liver Fibroses
Cardiovascular Diseases
Cardiovascular Risk Factor
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 80
- Sex
- Any
- Study type
- Observational
- Participants needed
- 2,000 (estimated)
- Sponsor
- University of Roma La Sapienza · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Liver fibrosis is the most important prognostic factor in patients with non-alcoholic factor disease. Clinical and biological condition, as diabetes or mutation for PNPLA3, are well known factors associated with liver fibrosis onset and progression. However, little is known about biochemical factors predicting liver fibrosis evolution in large NAFLD populations.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients aged 18 years old or more
* Patients with at least on of the following metabolic disorders
* Obesity
* Diabetes
* Arterial hypertension
* Dyslipidemia
Exclusion Criteria:
* Average daily consumption of alcohol \>20 g in women and of \>30 g in men (assessed …
Contacts